Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Raskin

Showing results (1-10 of 125) with videos related to

Pageof 13
Sort By:
Diabetes/Metabolism Research and Reviews|October 31, 2007
Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetesPhilip Raskin
Diabetes/Metabolism Research and Reviews|March 7, 2013
Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitusPhilip Raskin
Diabetes Care|October 27, 2005
Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to JankaPhilip Raskin
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2006
Can glycemic targets be achieved-- in particular with two daily injections of a mix of intermediate- and short-acting insulin?Philip Raskin
Endocrinology and Metabolism Clinics of North America|October 16, 2007
Efficacy and safety of insulin detemirPhilip Raskin
Basic & Clinical Pharmacology & Toxicology|December 1, 2004
Glucagon-like peptide: the time is nearAlvin Huang, Philip Raskin
Journal of Diabetes and Its Complications|March 1, 2006
Hepatitis C infection and diabetesHiroshi Noto, Philip Raskin
Diabetes, Obesity & Metabolism|October 10, 2006
Novel insulin analogues and its mitogenic potentialIvana Zib, Philip Raskin
Expert Opinion on Pharmacotherapy|June 12, 2010
Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)Philip Raskin, Alok Mohan
Expert Opinion on Emerging Drugs|April 14, 2010
Emerging treatments for the prevention of type 1 diabetesPhilip Raskin, Alok Mohan
Pageof 13

Showing results (1-10 of 125) with videos related to

Sort By:
Pageof 13
Diabetes/Metabolism Research and Reviews|October 31, 2007
Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetesPhilip Raskin
Diabetes/Metabolism Research and Reviews|March 7, 2013
Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitusPhilip Raskin
Diabetes Care|October 27, 2005
Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to JankaPhilip Raskin
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 22, 2006
Can glycemic targets be achieved-- in particular with two daily injections of a mix of intermediate- and short-acting insulin?Philip Raskin
Endocrinology and Metabolism Clinics of North America|October 16, 2007
Efficacy and safety of insulin detemirPhilip Raskin
Basic & Clinical Pharmacology & Toxicology|December 1, 2004
Glucagon-like peptide: the time is nearAlvin Huang, Philip Raskin
Journal of Diabetes and Its Complications|March 1, 2006
Hepatitis C infection and diabetesHiroshi Noto, Philip Raskin
Diabetes, Obesity & Metabolism|October 10, 2006
Novel insulin analogues and its mitogenic potentialIvana Zib, Philip Raskin
Expert Opinion on Pharmacotherapy|June 12, 2010
Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)Philip Raskin, Alok Mohan
Expert Opinion on Emerging Drugs|April 14, 2010
Emerging treatments for the prevention of type 1 diabetesPhilip Raskin, Alok Mohan
Pageof 13